|
The case for upfront HLA-matched unrelated donor HCT as a curative option for adult acquired severe aplastic anemia: Upfront MUD HCT for adult severe aplastic anemia |
May 2019 |
Biology of Blood and Marrow Transplantation: Journal of the American Society of Blood and Marrow Transplantation |
Aplastic Anemia |
|
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial |
Jun 2019 |
The Lancet Haematology |
Myelodysplastic Syndromes (MDS) |
|
RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis |
Jun 2019 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
|
Activin Receptor II Ligand Traps: New Treatment Paradigm for Low-Risk MDS |
Jun 2019 |
Current Hematologic Malignancy Report |
Myelodysplastic Syndromes (MDS) |
|
A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients |
Jun 2019 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
Defining the Boundary Between Myelodysplastic Syndromes and Myeloproliferative Neoplasms |
Jul 2019 |
Surgical Pathology Clinic |
Myelodysplastic Syndromes (MDS) |
|
Management of aplastic anemia after failure of frontline immunosuppression |
Jul 2019 |
Expert Review of Hematology |
Aplastic Anemia |
|
Phase 2 Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes |
Sep 2019 |
Clinical Cancer Research: an official Journal of the American Association of Cancer Research |
Myelodysplastic Syndromes (MDS) |
|
Germline DDX41 mutations define a significant entity within adult MDS/AML patients |
Sep 2019 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria |
Sep 2019 |
Therapeutic Advances in Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
